BLATOPICALOINTMENT
Approved
Apr 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELASE-CHLOROMYCETIN is a combination topical ointment containing chloramphenicol (broad-spectrum antibiotic), desoxyribonuclease (enzymatic debridement agent), and fibrinolysin (fibrin-dissolving enzyme). This product is indicated for infected wounds, ulcers, and burn surfaces where enzymatic debridement and antimicrobial activity are needed. The combination works synergistically to remove necrotic tissue and prevent bacterial infection in topical wounds.
LOE Approaching
With lifecycle status approaching loss of exclusivity and competitive pressure at 30%, this product is in transition; commercial teams are likely focused on defending existing market position rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ELASE-CHLOROMYCETIN offers limited growth trajectory given its LOE-approaching lifecycle status; roles focus on defending market share, managing relationships with healthcare providers, and ensuring regulatory compliance rather than driving innovation. This product is suited for early-career professionals seeking foundational commercial experience or specialists in niche wound care markets seeking stability in a mature therapeutic area.
Brand Manager
Worked on ELASE-CHLOROMYCETIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.